# An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

> **NCT04353492** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 562 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Ofatumumab

## Key facts

- **NCT ID:** NCT04353492
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2024-10-09
- **Final completion:** 2025-03-11
- **Target enrollment:** 562 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353492, "An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04353492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*